scholarly journals 131I-chTNT injection to relieve tracheal obstruction in advanced NSCLC patient

2016 ◽  
Vol 24 (s2) ◽  
pp. S513-S519 ◽  
Author(s):  
Mengzhang He ◽  
Shiyue Li ◽  
Yu Chen ◽  
Ming Ouyang ◽  
Ping Chen ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Nsclc Patient ◽  
Tracheal Obstruction ◽  
Advanced Nsclc Patient

scholarly journals RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient

Lung Cancer ◽  
2021 ◽  
Vol 151 ◽  
pp. 101-103
Author(s):  
Sayaka Arakawa ◽  
Tatsuya Yoshida ◽  
Masayuki Shirasawa ◽  
Daisuke Takayanagi ◽  
Shigehiro Yagishita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Nsclc Patient ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Advanced Nsclc Patient

scholarly journals P84.21 Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient

2021 ◽  
Vol 16 (3) ◽  
pp. S667
Author(s):  
F. Duarte ◽  
L. Rodrigues ◽  
F. Paes ◽  
P. Diniz ◽  
H. De Almada
Keyword(s):  
Advanced Nsclc ◽  
Nsclc Patient ◽  
Advanced Nsclc Patient

scholarly journals LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii8-iii8
Author(s):  
Hui Wang ◽  
Changguo Shan ◽  
Weiping Hong ◽  
Lei Wen ◽  
Mingyao Lai ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Kinase Inhibitor ◽  
Nsclc Patient ◽  
Growth Factor Receptor ◽  
Leptomeningeal Metastasis ◽  
Egfr Mutations ◽  
Optimal Dosage ◽  
Durable Response ◽  
Disturbance Of Consciousness ◽  
Nsclc Patients

Abstract Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. However, the efficacy and optimal dosage of osimertinib in the treatment of NSCLC patients with LM who harbor uncommon EGFR mutations have yet to be fully investigated. Herein, we report a case of an advanced NSCLC patient with LM carrying EGFR G719S and L861Q, who was successfully treated by osimertinib at 160 mg. The patient initially presented with clear cell renal carcinoma and renal metastatic adenocarcinoma, and underwent right nephrectomy. At 2 months after nephrectomy, He developed a disturbance of consciousness and was subsequently diagnosed with NSCLC with LM by meningeal biopsy pathology and cerebrospinal fluid (CSF) cytology. Next-generation sequencing detected the rare EGFR mutations G719S and L861R in the meningeal biopsy tissues. The patient was then administered osimertinib at 80 mg quaque die (QD); after 1 month of treatment, his symptoms were alleviated. However, two months later, he experienced epileptic episode. Subsequently, the osimertinib dosage was doubled to 160 mg QD. After 1 month of treatment, the patient achieved central nervous system (CNS) response, and at the time of this manuscript’s submission, he had maintained stable disease (SD) for more than 1 year. To our knowledge, this study provides the first clinical evidence that the administration of osimertinib at 160 mg once daily can achieve an encouraging, durable response in an NSCLC patients with LM carrying EGFR G719S and L861Q. Aslo, it is recommended to consider performing leptomeningeal biopsy for precision treatment in NSCLC paiernts with leptomeningeal metastasis.

Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 8011-8011
Author(s):  
F. A. Shepherd ◽  
J. Douillard ◽  
M. Fukuoka ◽  
N. Saijo ◽  
S. Kim ◽  
...  
Keyword(s):  
Clin Oncol ◽  
Proportional Hazards ◽  
Advanced Nsclc ◽  
Meta Analysis ◽  
Nsclc Patient ◽  
Cox Proportional Hazards ◽  
Tolerability Profile ◽  
Open Label ◽  
The Individual ◽  
Meta Analyses

8011 Background: Four open-label, randomized trials evaluated gefitinib (G) vs docetaxel (D) in unselected patients with pre-treated advanced NSCLC: INTEREST (Lancet 2008; 372: 1809), V-15–32 (J Clin Oncol 2008; 26: 4244), ISTANA (J Clin Oncol 2008; 26: Abs 8025), SIGN (Anticancer Drugs 2006; 17: 401). Reported here is a meta-analysis using the patient data from each of these trials. Methods: The meta-analysis compared efficacy of G (250 mg/day) and D (75 mg/m2 [V-15–32 60 mg/m2]) using appropriate analysis populations from INTEREST (1466 patients randomized), V-15–32 (489), ISTANA (161) and SIGN (141). Meta-analyses (unadjusted and adjusted for covariates) were performed by Cox proportional hazards for OS and PFS, and by logistic regression for ORR. Results: G demonstrated similar OS and PFS and superior ORR to D in the primary analyses. Secondary analyses demonstrated similar results. Conclusions: Results were consistent with those of the individual studies. Given the similar/superior efficacy demonstrated by G, its favorable tolerability profile, quality of life benefits and oral administration, G has a favorable benefit-risk profile compared with D in a broad pre-treated advanced NSCLC patient population. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document